Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report | JOURNAL OF MEDICAL Sr CASE REPORTS Open Access Case report Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab a case report Supen R Patel Address Carolina Health Care East Cheves Street Florence SC 29503 USA Email SUPEN1234@ Received 3 October 2008 Accepted 17 March 2009 Published 29 July 2009 Journal ofMedical Case Reports 2009 3 8573 doi 1752-1947-3-8573 This article is available from http jmedicalcasereports article view 8573 2009 Patel licensee Cases Network Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Introduction Sarcoidosis is an inflammatory disorder characterized by the presence of non-caseating granulomas in affected organs. The presence of CD4-positive T lymphocytes and macrophages in affected organs suggests an ongoing immune response. Systemic corticosteroids remain the mainstay of treatment but therapy is often limited by adverse effects. This is the first report of the use of adalimumab HUMIRA Abbott Laboratories North Chicago IL USA an antitumor necrosis factor monoclonal antibody in a patient with systemic sarcoidosis with bone marrow involvement. Case presentation A 42-year-old African-American man with a medical history significant for hypertension and diabetes mellitus presented with anemia and thrombocytopenia of two months duration. The patient underwent physical examination bone marrow aspiration and biopsy chest X-ray acid-fast bacilli stain computed tomography with contrast and additional laboratory tests. He was diagnosed with systemic sarcoidosis with splenomegaly and bone marrow involvement. Drug therapy included prednisone which had to be discontinued owing to adverse effects and adalimumab. Conclusion This is the first report .
